Preclinical Vaccine Study of Plasmodium vivax Circumsporozoite Protein Derived-Synthetic Polypeptides Formulated in Montanide ISA 720 and Montanide ISA 51 Adjuvants

Arévalo‐Herrera, Myriam; Vera, Omaira; Castellanos, Alejandro; Céspedes, Nora; Soto, L; Corradin, Giampietro; Herrera, Sócrates

doi:10.4269/ajtmh.2011.10-0110

Cited by 23 publications

(23 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although IFAT titers may appear low, the high seroconversion is encouraging because in field conditions only a limited number of the individuals continuously exposed to P. vivax recognize sporozoites, 51,52 even if they are continuously exposed to the complete mass of parasite proteins. Interestingly, similar antibody titers were indicated in a previous trial 53 to induce significant in vitro sporozoites invasion inhibition.…”

Section: Discussionsupporting

confidence: 81%

“…53 Moreover, titers were higher than those observed in sera of most people from P. vivax endemic areas of Colombia. 42 As we expected, IgG isotype profile response was different for each peptide.…”

Section: Discussionmentioning

confidence: 87%

“…Indeed, similar antibody titers were able to block in vitro parasite invasion. 53 Furthermore, the fact that Montanide ISA 51 elicited a more vigorous anti-sporozoite response than Montanide ISA 720 formulations should be considered when moving forward in designing further clinical trials with these peptides.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Phase I Safety and Immunogenicity Trial of Plasmodium vivax CS Derived Long Synthetic Peptides Adjuvanted with Montanide ISA 720 or Montanide ISA 51

Herrera¹,

Fernández²,

Vera³

et al. 2011

The American Journal of Tropical Medicine and Hygiene

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

Phase I Safety and Immunogenicity Trial of Plasmodium vivax CS Derived Long Synthetic Peptides Adjuvanted with Montanide ISA 720 or Montanide ISA 51

Herrera¹,

Fernández²,

Vera³

et al. 2011

The American Journal of Tropical Medicine and Hygiene

Self Cite

View full text Add to dashboard Cite

“…Montanide ISA720 is an oil-in-water synthetic adjuvant that has been repeatedly used in preclinical (4,12,15,20) and clinical (17,19,21,28,32,37,38,46,50) trials of different malaria vaccine candidates and in particular of P. falciparum AMA-1 (11,12,15,21,32,38,46,50). It is highly immunogenic and is able to induce significant humoral and cellular immune responses, even after a single immunization, although standard protocols consist of three doses of antigen in this adjuvant.…”

mentioning

confidence: 99%

Long-Term Humoral and Cellular Immune Responses Elicited by a Heterologous Plasmodium vivax Apical Membrane Antigen 1 Protein Prime/Adenovirus Boost Immunization Protocol

et al. 2011

View full text Add to dashboard Cite

Apical membrane antigen 1 (AMA-1) is an invasion-related Plasmodium antigen that is expressed during both intracellular and extracellular asexual stages of the parasite's life cycle, making it an ideal target for induction of humoral and cellular immune responses that can protect against malaria. We show here that when it is administered as a recombinant protein (P) in Montanide ISA720 adjuvant, followed by a recombinant human type 5 adenovirus (Ad), intense and long-lasting Plasmodium vivax AMA-1-specific antibody responses (including both IgG1 and IgG2a), as well as proliferative memory T cell responses, can be detected in immunized mice. Memory T cells displayed both central (CD44 hi CD62L hi ) and effector (CD44 hi CD62L lo ) phenotypes, with the central memory phenotype prevailing (56% of AMA-1-specific proliferating cells). Considering the main traits of the memory immune responses induced against AMA-1, this particular sequence of immunogens (P followed by Ad), but no others (Ad/Ad, Ad/P, or P/P), displayed an optimal synergistic effect. These results give further support to the need for preclinical studies of P. vivax vaccine candidate AMA-1 administered in prime/boost protocols that include recombinant proteins and adenoviral vectors.

show abstract

“…Recently, the construction of LSP (up to 185 residues) for vaccine development has contributed to the rapid production of clean, functional, synthetic proteins containing fragments that have induced specific immune responses in preclinical and clinical studies (Perlaza et al 2001, Herrera et al 2005a, 2011, Corradin et al 2010, Olugbile et al 2010, Arévalo-Herrera et al 2011b). …”

Section: Novel Approaches For Parasite Antigen Discoverymentioning

confidence: 99%

Platform for Plasmodium vivax vaccine discovery and development

Valencia

Rodríguez

Acero

et al. 2011

Mem. Inst. Oswaldo Cruz

Self Cite

View full text Add to dashboard Cite

Plasmodium vivax is the most prevalent malaria parasite on the American continent. It generates a global burden of 80–100 million cases annually and represents a tremendous public health problem, particularly in the American and Asian continents. A malaria vaccine would be considered the most cost-effective measure against this vector-borne disease and it would contribute to a reduction in malaria cases and to eventual eradication. Although significant progress has been achieved in the search for Plasmodium falciparum antigens that could be used in a vaccine, limited progress has been made in the search for P. vivax components that might be eligible for vaccine development. This is primarily due to the lack of in vitro cultures to serve as an antigen source and to inadequate funding. While the most advanced P. falciparum vaccine candidate is currently being tested in Phase III trials in Africa, the most advanced P. vivax candidates have only advanced to Phase I trials. Herein, we describe the overall strategy and progress in P. vivax vaccine research, from antigen discovery to preclinical and clinical development and we discuss the regional potential of Latin America to develop a comprehensive platform for vaccine development.

show abstract

Preclinical Vaccine Study of Plasmodium vivax Circumsporozoite Protein Derived-Synthetic Polypeptides Formulated in Montanide ISA 720 and Montanide ISA 51 Adjuvants

Cited by 23 publications

References 51 publications

Phase I Safety and Immunogenicity Trial of Plasmodium vivax CS Derived Long Synthetic Peptides Adjuvanted with Montanide ISA 720 or Montanide ISA 51

Phase I Safety and Immunogenicity Trial of Plasmodium vivax CS Derived Long Synthetic Peptides Adjuvanted with Montanide ISA 720 or Montanide ISA 51

Long-Term Humoral and Cellular Immune Responses Elicited by a Heterologous Plasmodium vivax Apical Membrane Antigen 1 Protein Prime/Adenovirus Boost Immunization Protocol

Platform for Plasmodium vivax vaccine discovery and development

Contact Info

Product

Resources

About